Abstract

The Leukocyte Adherence Inhibition (LAI) assay has been evaluated for clinical use in the management of patients with ovarian cancer. Studies on the tube method included determination of the optimal concentration of cells used and the type, or presence or absence, of serum supplement utilised; also the effect on LAI of various specific and non-specific crude antigen preparations. A refined assay was used to compare data from 21 patients with epithelial ovarian cancer, a miscellaneous group of other types of cancer and control groups of healthy pregnant and non-pregnant women of reproductive age. Positive LAI responses were produced in some patients with ovarian cancer, but there were no significant differences between the groups. It was concluded that lack of reactivity in patients with widespread disease, early loss of reactivity in remission, and moderation of the LAI index by concurrent therapy would limit the practical use of this assay to monitor the host response of patients with ovarian cancer.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.